Karyopharm Therapeutics Inc. - KPTI STOCK NEWS

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced that results from its Phase 1 study on selinexor combined with ruxolitinib for treatment-naïve myelofibrosis will be presented at the AACR Annual Meeting 2023. The combination therapy showed potential efficacy, with updates indicating a ≥35% reduction in spleen volume and a ≥50% reduction in symptom scores among 24 patients followed for 24 weeks. Safety data demonstrated the combination was generally well tolerated. An investor webcast is planned to discuss the study results, emphasizing the potential impact of XPO1 inhibition in myelofibrosis treatment.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a leader in cancer therapies, will participate in a fireside chat at the Barclays Global Healthcare Conference on March 15 at 4:35 p.m. ET. The event will feature insights from the company’s senior management team. Investors can access a live webcast and accompanying slides on the company’s Investor website, with a replay available for 90 days post-event. Karyopharm is known for its pioneering SINE compound technology and its lead product, XPOVIO®, which is approved in multiple oncology indications.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced the appointment of Tanya Lewis to its board of directors, effective March 1, 2023. With over 25 years in drug development, Ms. Lewis has a proven track record, having held leadership roles at Replimune Group and Karyopharm Therapeutics. Her experience includes overseeing the approval of several new drugs, including XPOVIO^®. The board welcomed her expertise at a pivotal time for DiaMedica as they work to address the clinical hold on their ReMEDy2 AIS trial. Ms. Lewis aims to support the company’s mission of providing treatment options for stroke patients.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced the granting of 111,250 restricted stock units (RSUs) to eight new employees as part of its 2022 Inducement Stock Incentive Plan on February 28, 2023. The RSUs will vest over three years with one-third vesting on each anniversary of employment. If a change in control event occurs, the RSUs can be exercised if employment is terminated for good reason or without cause. Karyopharm specializes in innovative cancer therapies, notably its lead XPO1 inhibitor, XPOVIO®, which is approved in various regions for multiple oncology indications.

Karyopharm Therapeutics (Nasdaq: KPTI) and Menarini Group announced that the UK's Medicines and Healthcare Products Regulatory Agency has granted full Marketing Authorization for NEXPOVIO® (selinexor) in combination with bortezomib and dexamethasone for treating adult patients with multiple myeloma who have had at least one prior therapy. This authorization converts the previous conditional approval to full status, based on results from the Phase 3 BOSTON study that showed significant improvements in disease progression. The Menarini Group will handle commercialization in the UK.

Karyopharm Therapeutics reported total revenue of $157.1 million for 2022, with U.S. XPOVIO® net product revenue of $120.4 million, meeting company guidance. The fourth quarter saw a 4% increase in net product revenue year-over-year. For 2023, the company anticipates total revenue between $160 million and $175 million, including U.S. XPOVIO projections of $125 million to $140 million. Cash reserves are expected to sustain operations until late 2025. The company also revealed advancements in its clinical pipeline, including key studies in myelofibrosis and myelodysplastic neoplasms, with interim data expected in the first half of 2023.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced participation in the virtual SVB Securities Global Biopharma Conference on February 16, 2023, at 11:20 a.m. ET. The senior management team will engage in a fireside chat, with a live webcast available for replay on the company's website for 90 days post-event. Karyopharm specializes in novel cancer therapies and is known for its lead compound, XPOVIO® (selinexor), which addresses nuclear export dysregulation in oncogenesis. The company also has a diverse pipeline targeting high unmet cancer needs in multiple myeloma, endometrial cancer, and more. For further details, visit www.karyopharm.com.

Karyopharm Therapeutics Inc. (NASDAQ: KPTI) announced it will release its fourth quarter and full year 2022 financial results on February 15, 2023, during a conference call at 8:00 a.m. ET. The call will cover financial results and company updates. Karyopharm is known for developing novel cancer therapies, including its lead compound, XPOVIO® (selinexor), which is approved in the U.S. for multiple oncology indications. The company is focused on addressing high unmet needs in cancer treatment.

Karyopharm Therapeutics (NASDAQ: KPTI) announced on February 1, 2023, the grant of 113,250 restricted stock units (RSUs) to ten newly hired employees as part of its 2022 Inducement Stock Incentive Plan. The RSUs will vest over three years, with one-third vesting each year, contingent upon the employees' continued service. These grants align with Nasdaq Listing Rule 5635(c)(4), offering incentives to attract talent. Karyopharm develops innovative cancer therapies, including XPOVIO® (selinexor), an oral exportin 1 inhibitor approved for multiple oncology indications in the U.S. and other regions.